107244-57-5

Usage

Appearance

Colorless to pale yellow solid at room temperature

Stability

Stable under normal conditions

Uses

Reagent in organic synthesis, potential applications in pharmaceutical and agricultural industries, and research and development for new chemical compounds

Safety precautions

Can be harmful if ingested or inhaled, may cause irritation to the skin and eyes, handle with caution.

Upstream product

• 88-69-7 2-(1-methylethyl)phenol 

Downstream Products

• 16750-66-6 2-iso-Propyl-4-aminophenol 
• 107244-72-4 4-amino-2-<(diethylamino)methyl>-6-(1-methylethyl)phenol dihydrochloride 
• 107244-89-3 4-[(7-chloro-4-quinolinyl)amino]-2-[(diethylamino)methyl]-6-(1-methylethyl)phenol N^ω oxide 
• 107244-81-5 4-(7-Chloro-quinolin-4-ylamino)-2-diethylaminomethyl-6-isopropyl-phenol 
• 107244-64-4 N-(3-Diethylaminomethyl-4-hydroxy-5-isopropyl-phenyl)-acetamide 
• 13780-91-1 N-(4-Hydroxy-3-isopropyl-phenyl)-acetamide 

Relevant academic research and scientific papers

Discovery and SAR study of 3-(tert-butyl)-4-hydroxyphenyl benzoate and benzamide derivatives as novel farnesoid X receptor (FXR) antagonists

3-(tert-Butyl)-4-hydroxyphenyl 2,4-dichlorobenzoate (1) was discovered in our in-house high throughput screening as a moderate FXR antagonist. To improve the potency and the stability of the hit 1, forty derivatives were synthesized and SAR was systematically explored. The results turn out that replacing the 2,4-dichlorophenyl with 2,6-dichloro-4-amidophenyl shows great improvement in potency, replacing the benzoate with benzamide shows improvement in stability and slight declining of potency and 3-(tert-butyl)-4-hydroxyphenyl unit is essential in obtaining the FXR antagonistic activity.

PYRROLIDINE DERIVATIVES AS ERK INHIBITORS

Disclosed are the ERK inhibitors of Formula (1.0): and the pharmaceutically acceptable salts and solvates thereof. Q is a piperidine or piperazine ring that can have a bridge or a fused ring. The piperidine ring can have a double bond in the ring. All other substitutents are as defined herein. Also disclosed are methods of treating cancer using the compounds of Formula (1.0).